ReShape Lifesciences (RSLS, Financial) has made a significant stride in strengthening its market position with a new patent grant, enhancing its intellectual property landscape.
- The company's intragastric balloon system patent extends protection until 2031.
- Current stock price of $0.43 presents a potential upside of 132.18%.
- Analysts maintain a "Hold" status with a $1.00 average price target.
Patent Strengthens Competitive Edge
The United States Patent and Trademark Office (USPTO) has awarded ReShape Lifesciences a Notice of Allowance for its advanced intragastric balloon system. This patent, poised to secure protection until 2031, bolsters the company's intellectual property portfolio. Such advancements are pivotal in enhancing ReShape’s competitive edge in the realms of weight loss and metabolic health solutions.
Wall Street Analysts Forecast
According to projections by one analyst, the one-year price target for Reshape Lifesciences Inc (RSLS, Financial) sits at $1.00, with both high and low estimates also at $1.00. This estimation suggests a remarkable upside potential of 132.18% from its current trading price of $0.43. For more detailed information regarding these forecasts, please visit the Reshape Lifesciences Inc (RSLS) Forecast page.
Brokerage Firm Recommendations
The consensus recommendation from one brokerage firm places Reshape Lifesciences Inc (RSLS, Financial) at an average brokerage recommendation of 3.0, which denotes a "Hold" status on their rating scale. This scale ranges from 1 to 5, where 1 reflects a Strong Buy and 5 indicates a Sell.
Investors should carefully consider this data as they evaluate the potential growth and risks of investing in ReShape Lifesciences.
